BioVie Inc. (BIVI)

BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript

What's Going On With BioVie Stock on Tuesday?

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

Dow closes sharply lower as oil surge fuels inflation fears

BioVie advances Parkinson's Phase 3 development program with FDA engagement

BioVie Announces Update to Parkinson's Phase 3 Development Program

Dow falls as US strikes Iran, rate-hike bets jump

BioVie completes final patient visit in Phase 2 Long COVID trial

BioVie completes final patient visit in Phase 2 Long COVID trial

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

Parkinson's drug developers are betting big on inflammation

Vaalco Energy quarter sales jump, ups guidance

Apple App Store revenue ticks up despite falling downloads

Uber price target lowered by Bank of America despite higher earnings outlook

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease